TABLE 2.
Quantification of TFV-DP in RBC-contaminated PBMC samples (prepared with or without the removal of RBC) from HIV-infected patients
| Patient | NRTI treatment | Time (h) postdose | % Contamination with RBCa | Concn (fmol/sample) of TFV-DP in:
|
Ratio of TFV-DP concn in nonlysed sample and lysed sample | |
|---|---|---|---|---|---|---|
| Nonlysed sample | RBC-lysed sample | |||||
| A1 | TFV | 2.0 | >200 | 849.6 | 395.4 | 2.15 |
| A2 | TFV | 9.5 | >200 | 1,287 | 182.5 | 7.05 |
| A3 | TFV | 2.0 | 50 | 302.6 | 376.6 | 0.80 |
a
To determine the level of contamination, the RBC/PBMC ratio was calculated and expressed as a percentage.